Bildkälla: Stockfoto

Active Biotech Q2’22: Our comments - Redeye

Redeye comments on Active Biotech's second quarter report and the rights issue that was simultaneously announced.

Redeye comments on Active Biotech's second quarter report and the rights issue that was simultaneously announced.
Börsvärldens nyhetsbrev
ANNONSER